Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.68 |
| ▸ | CDC25A | P30304 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.65 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696592 | 1.00 | CES1 (0.68) | CES1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL9626594 | 1.00 | CES1 (0.68) | CES1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL10731237 | 1.00 | CES1 (0.68) | CES1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL732925 | 1.00 | CES1 (0.68) | CES1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL10725536 | 1.00 | CES1 (0.68) | CES1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL23731163 | 1.00 | CES1 (0.68) | CES1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL8863090 | 1.00 | CES1 (0.68) | CES1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL8862943 | 1.00 | CES1 (0.68) | CES1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL8863074 | 1.00 | CES1 (0.68) | CES1CDC25AALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL31406188 | 1.00 | CES1 (0.68) | CES1CDC25AALDH1A1ALDH2ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5719295-A | FROM N-ALKYL NITROPHTHALAMIDE | GENERAL ELECTRIC COMPANY (US) | 1998-02-17 | — | — | US | claimed |
| US-5688312-A | INKS WITH COLORS AND IMIDES OR BISIMIDES, FOR ACOUSTIC INK PRINTER AND DROP EJECTOR | XEROX CORPORATION (US) | 1997-11-18 | — | — | US | claimed |
| WO-1990008137-A1 | PREPARATION OF IMIDES | EASTMAN KODAK COMPANY (US) | 1990-07-26 | — | — | WO | claimed |
| US-4933467-A | FROM CARBON MONOXIDE, AN O-DIHALO AROMATIC COMPOUND OR CIS-1,2-VINYL DIHALIDE AND PRIMARY AMINE, PALLADIUM CATALYST | EASTMAN KODAK COMPANY (US) | 1990-06-12 | — | — | US | claimed |
| CN-119894496-A | Component systems and methods for preparing tooth whitening formulations | 可碧股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| EP-4289883-A1 | CURABLE RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| US-10954217-B2 | Sigma receptor binders | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190177301-A1 | SIGMA RECEPTOR BINDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-06-13 | — | — | US | disclosed |
| WO-2018128720-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018098204-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| EP-0467248-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
| WO-1990008137-A1 | PREPARATION OF IMIDES | EASTMAN KODAK COMPANY (US) | 1990-07-26 | — | — | WO | disclosed |
| US-4933466-A | FROM CARBON MONOXIDE, IODOBENZENE, AND ARYL PRIMARY AMIDE | EASTMAN KODAK COMPANY (US) | 1990-06-12 | — | — | US | disclosed |
| US-4933467-A | FROM CARBON MONOXIDE, AN O-DIHALO AROMATIC COMPOUND OR CIS-1,2-VINYL DIHALIDE AND PRIMARY AMINE, PALLADIUM CATALYST | EASTMAN KODAK COMPANY (US) | 1990-06-12 | — | — | US | disclosed |
| US-RE32868-E | Antihyperlipidemic compositions | RESEARCH CORPORATION (US) | 1989-02-14 | — | — | US | disclosed |
| US-4395417-A | Antihyperlipidemic compositions | RESEARCH CORPORATION (US) | 1983-07-26 | — | — | US | disclosed |
| US-3993437-A | Process for the dyeing of polyamide fibers with sulphur dyestuffs | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1976-11-23 | — | — | US | disclosed |
| US-3966726-A | Process for the production of cyclic carboxylic acid imides | AKZO N.V. (NL) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | CES1 324/4885CDC25A 4882/4885ALDH1A1 1354/4885 |
| US-10954217-B2 | Sigma receptor binders | SIGMAR1, OPRK1, OPRL1 | CES1 2183/4885CDC25A 4637/4885ALDH1A1 307/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | CES1 324/4885CDC25A 4882/4885ALDH1A1 1354/4885 |
| US-20190177301-A1 | SIGMA RECEPTOR BINDERS | SIGMAR1, OPRK1, OPRL1 | CES1 2183/4885CDC25A 4637/4885ALDH1A1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.